Raseglurant, aslo known as ADX-10059, is a negative allosteric modulator of the mGlu5 receptor and derivative of MPEP which was under development by Addex Therapeutics for the treatment of migraine, gastroesophageal reflux disease, and dental anxiety. It reached phase II clinical trials for all of the aforementioned indications before being discontinued due to the observation of possible predictive signs of hepatotoxicity in patients with long-term use.
MedKoo Cat#: 319678
Name: Raseglurant free base
CAS#: 757950-09-7 (free base)
Chemical Formula: C15H13FN2
Exact Mass: 240.1063
Molecular Weight: 240.28
Elemental Analysis: C, 74.98; H, 5.45; F, 7.91; N, 11.66
The following data is based on the product molecular weight 240.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
